Cardiovascular diseases are the number one cause of death globally.
Worldwide, over 30% of all deaths are attributable to cardiovascular disease (CVD).1 The increasing incidence and high cost of care of CVDs demands a global approach to prevention, early detection & treatment, and monitoring of disease progression. Used in conjunction with clinical information, cardiac biomarkers are crucial to support rapid and accurate diagnosis, especially in acute cases where every minute counts.2-5
As market leader in cardiac biomarkers,6 Roche offers diagnostic tests for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF).
Partner with the pioneers for earlier, more confident clinical decision making
Roche has been the pioneer in in vitro diagnostic tests for CVD decision making for over 30 years. That’s why by partnering with Roche you get the benefit of our continual investment to enhance performance, clinical evidence, and reliability. This will support earlier & more confident clinical decision making, improved patient management, and increased efficiency & cost management.